East Asia Pharmaceutical Co., Ltd. (605177.SH) released its financial results for the first half of the year, with a net profit of 30.22 million yuan, turning from profit to loss.

ChiNext Finance APP News, Dongya Pharmaceutical (605177.SH) released its 2025 semi-annual report, with the company's operating income of 416 million yuan, a year-on-year decrease of 35.85%. The net loss attributable to shareholders of the listed company was 30.2283 million yuan. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 35.8809 million yuan. Basic loss per share was 0.26 yuan. During the reporting period, operating income decreased by 35.85% year-on-year, mainly due to a decrease in downstream customer demand for -lactam antibiotics.